Dr. Reddy’s, Rheoscience Announce Results From First Phase III Balaglitazone Trial

Dr. Reddy’s Laboratories Ltd. and Rheoscience, a subsidiary of Nordic Bioscience A/S, Monday announced the headline results from the first phase III study for their investigational agent, Balaglitazone.
RTTNews